Association of early tumor shrinkage with survival in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan.

被引：0
|
作者：
Fukuda, Koshiro
Ooki, Akira
Osumi, Hiroki
Fukuoka, Shota
Yoshino, Koichiro
Tamba, Mikako
Udagawa, Shohei
Shimozaki, Keitaro
Ogura, Mariko
Wakatsuki, Takeru
Chin, Keisho
Fujishiro, Mitsuhiro
Shinozaki, Eiji
Yamaguchi, Kensei
机构：
[1] Canc Inst Hosp Japanese Fdn Canc Res, Dept Gastroenterol Chemotherapy, Tokyo, Japan
[2] Canc Inst Hosp Japanese Fdn Canc Res, Dept Gastroenterol Chemotherapy, Koto, Japan
[3] Univ Tokyo, Dept Gastroenterol, Tokyo, Japan
[4] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.360
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：360 / 360
页数：1
相关论文
共 50 条
  • [41] Trastuzumab In HER2-Positive Metastatic Gastric Cancer
    Croxtall, Jamie D.
    McKeage, Kate
    DRUGS, 2010, 70 (17) : 2259 - 2267
  • [42] ECONOMIC EVALUATION OF TRASTUZUMAB DERUXTECAN FOR HER2+ADVANCED GASTRIC CANCER PATIENTS
    Mudumba, R.
    Chan, H.
    Ballreich, J.
    VALUE IN HEALTH, 2023, 26 (12) : S151 - S152
  • [43] Successful second conversion surgery after trastuzumab deruxtecan for recurrent HER2-positive gastric cancer
    Terashima, Takeshi
    Yamashita, Tatsuya
    Takabatake, Hisashi
    Nakanuma, Shinichi
    Kinoshita, Jun
    Yagi, Shintaro
    Mizukoshi, Eishiro
    Harada, Kenichi
    Fushida, Sachio
    Kaneko, Shuichi
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2023, 16 (03) : 330 - 335
  • [44] Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer: A Case Report
    Ogata, Takatsugu
    Fujita, Yasuko
    Muro, Kei
    AMERICAN JOURNAL OF CASE REPORTS, 2022, 23
  • [45] Successful second conversion surgery after trastuzumab deruxtecan for recurrent HER2-positive gastric cancer
    Takeshi Terashima
    Tatsuya Yamashita
    Hisashi Takabatake
    Shinichi Nakanuma
    Jun Kinoshita
    Shintaro Yagi
    Eishiro Mizukoshi
    Kenichi Harada
    Sachio Fushida
    Shuichi Kaneko
    Clinical Journal of Gastroenterology, 2023, 16 : 330 - 335
  • [46] Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy
    Jun Zhou
    Zhi Peng
    Yi Liu
    Jifang Gong
    Xiaotian Zhang
    Ming Lu
    Jing Gao
    Yili Li
    Yanyan Li
    Lin Shen
    Journal of Gastroenterology, 2015, 50 : 955 - 961
  • [47] Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy
    Zhou, Jun
    Peng, Zhi
    Liu, Yi
    Gong, Jifang
    Zhang, Xiaotian
    Lu, Ming
    Gao, Jing
    Li, Yili
    Li, Yanyan
    Shen, Lin
    JOURNAL OF GASTROENTEROLOGY, 2015, 50 (09) : 955 - 961
  • [48] Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
    Antonarelli, G.
    Corti, C.
    Salimbeni, B. T.
    Tarantino, P.
    Zagami, P.
    Marra, A.
    Trapani, D.
    Tolaney, S.
    Cortes, J.
    Curigliano, G.
    ESMO OPEN, 2023, 8 (04)
  • [49] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Nie, Tina
    Blair, Hannah A.
    TARGETED ONCOLOGY, 2023, 18 (03) : 463 - 470
  • [50] Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?
    Roodhart, Jeanine M. L.
    Koopman, Miriam
    LANCET ONCOLOGY, 2024, 25 (09): : 1104 - 1105
12345